Prosecution Insights
Last updated: November 04, 2026
Application No. 18/823,194

FEED ADDITIVE

Non-Final OA §103§112
Filed
Sep 03, 2024
Priority
Sep 25, 2018 — JP 2018-178878 +2 more
Examiner
KOHUTKA, BROOKE NICOLE
Art Unit
3791
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Takao Onishi
OA Round
1 (Non-Final)
36%
Grant Probability
At Risk
1-2
OA Rounds
1y 9m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants only 36% of cases
36%
Career Allowance Rate
12 granted / 33 resolved
-33.6% vs TC avg
Strong +92% interview lift
Without
With
+92.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
44 currently pending
Career history
100
Total Applications
across all art units

Statute-Specific Performance

§101
8.6%
-31.4% vs TC avg
§103
35.1%
-4.9% vs TC avg
§102
22.5%
-17.5% vs TC avg
§112
33.0%
-7.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 33 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority Acknowledgment is made of applicant’s claim for foreign priority under 35 U.S.C. 119 (a)-(d). The certified copy has been filed in parent Application No. 17/274,347, filed on 8 March 2021. Specification The abstract of the disclosure is objected to because: -Line 1 recites “an feed additive” and should possibly read –a feed additive— A corrected abstract of the disclosure is required and must be presented on a separate sheet, apart from any other text. See MPEP § 608.01(b). Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-12 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. -Claim 1 recites “the onset of estrus” in line 7. There is insufficient antecedent basis for this limitation in the claim. -Claim 5 recites “the onset of estrus” in line 7. There is insufficient antecedent basis for this limitation in the claim. -Claim 9 recites “the onset of estrus” in line 8. There is insufficient antecedent basis for this limitation in the claim. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1, 2, 3, 5, 6, and 7 is/are rejected under 35 U.S.C. 103 as being unpatentable over Nomoto (JP 2015218121) in view of Dos Santos (WO 02081693). Regarding Claim 1, Nomoto teaches a method for improving the quality of embryos of a mammal obtained after a superovulation treatment and an artificial insemination treatment of the mammal [0009], [0003], [0020]—reference to improved ovarian function and [0021], the method comprising: administering follicle stimulating hormone to the mammal for causing superovulation [0020]—reference to hormone therapy applied to all mothers; wherein the mammal is reared under continuous feeding, over the period of 60 days or more [0010]—reference to 20 to 90 days, with a feed having added thereto a mammalian feed additive consisting of a licorice extract [0009], and wherein the licorice extract is administered to the mammal at a dose of 10 to 40 g/day/head [0010]. Nomoto is silent on administering prostaglandin F2α to the mammal for causing estrus; subjecting the mammal to artificial insemination after the onset of estrus; and collecting transplantable embryo(s) and/or egg(s) generated by the artificial insemination from the mammal by uterine flushing, until the collection of the embryo(s) and/or egg(s). Dos Santos teaches on administering prostaglandin F2α to the mammal for causing estrus [Pgs. 15-16; “estrus identification…utilize prostaglandin F2α…after estrus.”]; subjecting the mammal to artificial insemination after the onset of estrus [Pgs. 15-16; “estrus identification…10th day after estrus…two artificial insemination 12 and 24 hours after...estrus.”]; and collecting transplantable embryo(s) and/or egg(s) generated by the artificial insemination from the mammal by uterine flushing [Pg. 2, lines 13-16], until the collection of the embryo(s) and/or egg(s) [Pg. 15, “The embryo harvest…”]. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to administer prostaglandin to the mammal to cause estrus prior to subjecting the mammal to artificial insemination as taught by Dos Santos in combination with the method disclosed by Nomoto to obtain superovulation with better results (Dos Santos; [Abstract]). Regarding Claim 2, Nomoto further teaches wherein the mammal is a cow [0009]. Regarding Claim 3, Nomoto further teaches wherein the licorice extract is administered at a dose of 20 g/day/head [0010]. Regarding Claim 5, Nomoto teaches a method for improving the quality of embryos of a mammal obtained after a superovulation treatment and an artificial insemination treatment of the mammal [0009], [0003], [0020]—reference to improved ovarian function and [0021], the method comprising: administering follicle stimulating hormone to the mammal for causing superovulation [0020]—reference to hormone therapy applied to all mothers; wherein the mammal is reared under continuous feeding, over the period of 60 days or more [0010]—reference to 20 to 90 days, with a feed having added thereto a mammalian feed additive consisting of a licorice extract [0009], wherein the licorice extract is administered to the mammal at a dose of 10 to 40 g/day/head [0010], and Nomoto is silent on administering prostaglandin F2α to the mammal for causing estrus; subjecting the mammal to artificial insemination after the onset of estrus; and collecting transplantable embryo(s) and/or egg(s) generated by the artificial insemination from the mammal by uterine flushing, until the collection of the embryo(s) and/or egg(s), wherein the collected embryo(s) have an increased number of transferable embryos compared to embryos collected from a mammal not reared under continuous feeding with the feed having added thereto the mammalian feed additive. Dos Santos teaches administering prostaglandin F2α to the mammal for causing estrus [Pgs. 15-16; “estrus identification…utilize prostaglandin F2α…after estrus.”]; subjecting the mammal to artificial insemination after the onset of estrus Pgs. 15-16; “estrus identification…10th day after estrus…two artificial insemination 12 and 24 hours after...estrus.”]; and collecting transplantable embryo(s) and/or egg(s) generated by the artificial insemination from the mammal by uterine flushing [Pg. 2, lines 13-16], until the collection of the embryo(s) and/or egg(s) [Pg. 15, “The embryo harvest…”], wherein the collected embryo(s) have an increased number of transferable embryos compared to embryos collected from a mammal not reared under continuous feeding with the feed having added thereto the mammalian feed additive [Pg. 10, lines 12-17] and [Pg. 4, lines 22-24]. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to administer prostaglandin to the mammal to cause estrus prior to subjecting the mammal to artificial insemination as taught by Dos Santos in combination with the method disclosed by Nomoto to obtain superovulation with better results (Dos Santos; [Abstract]). Regarding Claim 6, Nomoto further teaches wherein the mammal is a cow [0009]. Regarding Claim 7, Nomoto further teaches wherein the licorice extract is administered at a dose of 20 g/day/head [0010]. Claim(s) 4 and 8 is/are rejected under 35 U.S.C. 103 as being unpatentable over Nomoto (JP 2015218121) in view of Dos Santos (WO 02081693) and in further view of Mae (CN 1479626). Regarding Claim 4, Nomoto and Dos Santos are silent on wherein the licorice extract has a glycyrrhizic acid content of at least 2.5 %. Mae teaches wherein the licorice extract has a glycyrrhizic acid content of at least 2.5 % [0056]. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to use licorice extract with a glycyrrhizic acid content of at least 2.5% as taught by Mae in combination with the method disclosed by Nomoto and modified by Dos Santos to prevent unwanted health effects such as diabetes and obesity (Mae; [0062-0063]). Regarding Claim 8, Nomoto and Dos Santos are silent on wherein the licorice extract has a glycyrrhizic acid content of at least 2.5 %. Mae teaches wherein the licorice extract has a glycyrrhizic acid content of at least 2.5 % [0056]. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to use licorice extract with a glycyrrhizic acid content of at least 2.5% as taught by Mae in combination with the method disclosed by Nomoto and modified by Dos Santos to prevent unwanted health effects such as diabetes and obesity (Mae; [0062-0063]). Claim(s) 9, 10, 11 is/are rejected under 35 U.S.C. 103 as being unpatentable over Nomoto (JP 2015218121) in view of Dos Santos (WO 02081693) and in further view of Huang et al. Administration of an herbal powder based on traditional Chinese veterinary medicine enhanced the fertility of Holstein dairy cows affected with retained placenta, Theriogenology, 121, 67-71, August 7 2018. Regarding Claim 9, Nomoto teaches a method for improving the quality of embryos of a mammal obtained after a superovulation treatment and an artificial insemination treatment of the mammal [0009], [0003], [0020]—reference to improved ovarian function and [0021], the method comprising: wherein the mammal is reared under continuous feeding, over the period of 60 days or more [0010]—reference to 20 to 90 days, with a feed having added thereto a mammalian feed additive consisting of a licorice extract [0009], and wherein the licorice extract is administered to the mammal at a dose of 10 to 40 g/day/head [0010]. Nomoto is silent on administering follicle stimulating hormone to the mammal by intramuscular injection for causing superovulation on 3 consecutive days with diminishing dosages; administering prostaglandin F2α to the mammal for causing estrus; subjecting the mammal to artificial insemination after the onset of estrus; and collecting transplantable embryo(s) and/or egg(s) generated by the artificial insemination from the mammal by uterine flushing, until the collection of the embryo(s) and/or egg(s). Dos Santos teaches administering follicle stimulating hormone to the mammal by intramuscular injection for causing superovulation on 3 consecutive days with diminishing dosages [Pg. 9, lines 3-10] and [Pg. 17, lines 25-27]; administering prostaglandin F2α to the mammal for causing estrus [Pgs. 15-16; “estrus identification…utilize prostaglandin F2α…after estrus.”] subjecting the mammal to artificial insemination after the onset of estrus [Pgs. 15-16; “estrus identification…10th day after estrus…two artificial insemination 12 and 24 hours after...estrus.”]; and collecting transplantable embryo(s) and/or egg(s) generated by the artificial insemination from the mammal by uterine flushing [Pg. 2, lines 13-16], until the collection of the embryo(s) and/or egg(s) [Pg. 15, “The embryo harvest…”]. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to administer prostaglandin to the mammal to cause estrus prior to subjecting the mammal to artificial insemination as taught by Dos Santos in combination with the method disclosed by Nomoto to obtain superovulation with better results (Dos Santos; [Abstract]). Nomoto and Dos Santos are silent on the 3rd day of the 3 consecutive days for the administrations of follicle stimulating hormone; Huang et al. teaches on the 3rd day of the 3 consecutive days for the administrations of follicle stimulating hormone [Abstract] and [Section 2.3]. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to administer in 3 consecutive day increments the FSH and prostaglandin as taught by Huang in combination with the method disclosed by Nomoto and as modified by Dos Santos to work in accordance with FSH half-life and necessity to use large or frequent doses (Dos Santos; [Pg. 9, lines 3-5]). Regarding Claim 10, Nomoto further teaches wherein the mammal is a cow [0009]. Regarding Claim 11, Nomoto further teaches wherein the licorice extract is administered at a dose of 20 g/day/head [0010]. Claim(s) 12 is/are rejected under 35 U.S.C. 103 as being unpatentable over Nomoto (JP 2015218121) in view of Dos Santos (WO 02081693) and Huang et al. Administration of an herbal powder based on traditional Chinese veterinary medicine enhanced the fertility of Holstein dairy cows affected with retained placenta, Theriogenology, 121, 67-71, August 7 2018 and further in view of Mae (CN 1479626). Regarding Claim 12, Nomoto, Dos Santos, and Huang et al. are silent on wherein the licorice extract has a glycyrrhizic acid content of at least 2.5 %. Mae teaches wherein the licorice extract has a glycyrrhizic acid content of at least 2.5 % [0056]. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to use licorice extract with a glycyrrhizic acid content of at least 2.5% as taught by Mae in combination with the method disclosed by Nomoto and modified by Dos Santos and Huang et al. to prevent unwanted health effects such as diabetes and obesity (Mae; [0062-0063]). Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. -Ghosh (DE 202006000487)—discloses methods of triggering estrus in cows through use of a preparation including licorice root -Okumura (U.S. 20180360899)—discusses use of licorice extract in treating obesity -Tung et al. Improved In Vitro Fertilization Ability of Mouse Sperm Caused by the Addition of Licorice Extract to the Preincubation Medium, The Open Reproductive Science Journal, 6, 1-7, 2014. —references similar method to that of the instant application but for use in mice. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BROOKE NICOLE KOHUTKA whose telephone number is (571)272-5583. The examiner can normally be reached Monday-Friday 7:30am-5:00pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Charles Marmor II can be reached at 571-272-4730. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /B.N.K./Examiner, Art Unit 3791 /CARRIE R DORNA/Primary Examiner, Art Unit 3791
Read full office action

Prosecution Timeline

Sep 03, 2024
Application Filed
Oct 19, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12734372
APPARATUS AND METHOD FOR GENERATING A MAGNETIC FIELD
3y 9m to grant Granted Sep 15, 2026
Patent 12697122
IMPLANTABLE SPHINCTER ASSISTANCE DEVICE WITH SHELL-TO-SHELL ORIENTATION CONTROLLED BY FIELDS OF ADJACENT MAGNETS
4y 7m to grant Granted Aug 04, 2026
Patent 12642531
IMPLANTABLE SPHINCTER ASSISTANCE DEVICE WITH DUAL ZONE CONTROLLED RATE OF CONSTRICTION FORCE
4y 5m to grant Granted Jun 02, 2026
Patent 12582402
IMPLANTABLE SPHINCTER ASSISTANCE DEVICE WITH SINGLE USE EMERGENCY RELEASE DECOUPLING INTERCONNECTION LINK
4y 3m to grant Granted Mar 24, 2026
Patent 12575832
IMPLANTABLE SPHINCTER ASSISTANCE DEVICE WITH 3D PRINTED OR MIM UNIBODY HOUSING
4y 3m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
36%
Grant Probability
99%
With Interview (+92.3%)
3y 11m (~1y 9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 33 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month